Business
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will take place September 12–14, 2022. \n\n \n \n \n \n \n \n\n \nThe presentation will be available on-demand beginning September 12, 2022 through the Investors section of Akebia's website at https://ir.akebia.com for approximately 90 days. \nAbout Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.\nAkebia Therapeutics ContactMercedes [email protected] \n \n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-virtually-at-the-hc-wainwright-24th-annual-global-investment-conference-301615782.html\nSOURCE Akebia Therapeutics","length":3549,"tagName":"div"}]